AnaSpec Introduces New Line of LL-37 GO™ Peptides

LL-37 peptides are AnaSpec’s latest addition to their expansive collection of research-ready, on-demand GO™ Peptides.

San Jose, CA, November 27, 2008 --(PR.com)-- LL-37 peptides are AnaSpec’s latest addition to their expansive collection of research-ready, on-demand GO™ Peptides. The LL-37 GO™ collection includes LL-37 fragments consisting of 8-37 and 18-37; FAM, biotin-LC-labeled LL-37 (LC is a 6-carbon linker); and Cys-LC-LL-37 - useful in applications such as conjugation to resin. Sepharose linked LL-37 is available as a custom order. New antimicrobial peptides (AMP) include Dermcidin, DCD-1L and mCRAMP, biotin-LC labeled.

Cathelicidins are cationic peptides that have broad-range antimicrobial activity.1 These peptides belong to the family of anti-microbial peptides which form part of the host’s important innate immunity mechanism.2 In humans, cathelicidins and defensins are expressed in immune cells and at epithelial surfaces.3-5 hCAP18, human cationic antimicrobial protein, with a MW of 18 kD, is the only cathelicidin gene found in humans.2 The N-terminus of this protein consists of a cathelin-like region (highly conserved among species) and a C-terminal termed LL-37.6-7 An amphipathic alpha-helical peptide, LL-37 plays an important role in the first line of defense against local infection and systemic invasion of pathogens at sites of inflammation and wounds. Cytotoxic to both bacterial and normal eukaryotic cells, LL-37 is significantly resistant to proteolytic degradation in solution.8-9 In addition to having antimicrobial activity, LL-37 has been shown to play a role in chemoattraction, dendritic cell differentiation, mast cell degranulation, cytokine secretion, angiogenesis stimulation, and wound healing.10 In other species, the C-terminal antimicrobial region varies in sizes, sequences and structures. 10
About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

For more information visit www.anaspec.com

References:
1. Zanetti, M. et al. J. Biol. Chem. 268, 522 (1993).
2. Lehrer, R. and T. Ganz. Curr. Opin. Immunol. 11, 23 (1999).
3. Ganz, T. Nat. Rev. Immunol. 3, 710 (2003).
4. Zanetti, M. J. Leukoc. Biol. 75, 39 (2004).
5. Chromek, M. et al. Nature Medicine 12, 636 (2006).
6. Zanetti, M. et al. FEBS Lett. 374, 1 (1995).
7. Sorensen, OE. et al. Blood 97, 3951 (2001).
8. Neville, F. et al. Biophys. J. 90, 1275 (2006)
9. Oren, Z., et al. Biochem. J. 341, 501(1999).
10. Gordon, YJ. et al. Curr. Eye Res. 30, 385 (2005).

###
Contact
AnaSpec, Inc.
Ping Yang
408-452-5055
www.anaspec.com
ContactContact
Categories